AMENDMENTS TO THE CLAIMS

1.-15. (Cancelled)

16. (Currently Amended) A method to treat ~~or prevent~~ a src-associated cancer comprising administering to an individual a proteinaceous cross-linking agent capable of cross-linking at least two molecules of the protein tyrosine phosphatase Sap-1.

17. (Cancelled)

18. (Previously Presented) The method of claim 16, wherein the cancer is a gastrointestinal cancer.

19. (Previously Presented) The method of claim 18, wherein the gastrointestinal cancer is selected from the group consisting of esophageal tumor, stomach cancer, small-bowel tumor, large-bowel tumor, and pancreatic cancer.

20. (Canceled)

21. (Currently Amended) The method of claim 16 ~~20~~, wherein the proteinaceous cross-linker is an antibody directed against the extra-cellular domain of Sap-1.

22. (Previously Presented) The method of claim 21, wherein the antibody is directed against a Fibronectin-type III like domain of Sap-1.

23. (Currently Amended) The method of claim 16 ~~20~~, wherein the cross-linking agent is a monoclonal antibody.

24. (Currently Amended) The method of claim ~~claims~~ 21, wherein the cross-linking agent is a monoclonal antibody.

25. (Currently Amended) The method of claim 16 ~~20~~, wherein the cross-linking agent is a humanized antibody.

26. (Currently Amended) The method of claim ~~claims~~ 21, wherein the cross-linking agent is a humanized antibody.

27. (Currently Amended) The method of claim 16 ~~20~~, wherein the cross-linking agent is a human antibody.

28. (Currently Amended) The method of claim ~~claims~~ 21, wherein the cross-linking agent is a human antibody.

29. (Currently Amended) The method of claim 16 ~~20~~, wherein the cross-linking agent is a soluble fragment of the extracellular domain of Sap-1.

30. (Currently Amended) The method of claim 16 ~~20~~, wherein the cross-linking agent comprises one, two, three, four, five, six, seven or eight Fibronectin-type III like repeats of Sap-1.

31. (Currently Amended) The method of claim 16 ~~20~~, wherein the cross-linking agent is selected from the group consisting of: a mutein of the proteinaceous cross-linking agent, a fused protein of the proteinaceous cross-linking agent, a functional derivative of the proteinaceous cross-linking agent, an active fraction of the proteinaceous cross-linking agent, and salt of the proteinaceous cross-linking agent.

32. (Currently Amended) The method of claim 16 ~~20~~, wherein the cross-linking agent is a functional derivative of the proteinaceous cross-linking agent comprising at least one moiety attached to one or more functional groups, which occur as one or more side chains on the amino acid residues.

33. (Previously Presented) The method of claim 32, wherein the moiety is a polyethylene moiety.

34. (New) A method for inhibiting the catalytic activity of the protein tyrosine phosphatase Sap-1 in a cell, comprising administering to the cell a cross-linking agent capable of cross-linking at least two molecules of the Sap-1.

35. (New) The method of claim 34, wherein the cross-linking agent is a proteinaceous cross-linking agent.

36. (New) The method of claim 35, wherein the cross-linking agent is a monoclonal antibody.

37. (New) A method for inhibiting the activation of or deactivating c-src in a cell, comprising administering to the cell a cross-linking agent capable of cross-linking at least two molecules of the Sap-1.

38. (New) The method of claim 37, wherein the cross-linking agent is a proteinaceous cross-linking agent.

39. (New) The method of claim 38, wherein the cross-linking agent is a monoclonal antibody.